LSD reduces anxiety for 4 months

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.

They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.

Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.

PDF of article

Activists arrested at DEA protest

Protestors of psilocybin ban arrested at DEA headquarters

At least 17 activists were arrested for protesting at the DEA headquarters. The purpose of the protest was to raise awareness about the DEA’s obstruction of access to psilocybin therapy, which should be legal for terminally ill patients through the Right to Try (RTT) laws.

“There is urgent need for the DEA to accommodate RTT and enable access (to psilocybin). This demonstration shines the bright light of public concern and outrage on this agency’s conduct,” says Kathryn Tucker, the attorney behind the litigation.

PDF of article

Science-backed psychedelic experiences

Leveraging over 20 years of psychedelic research, Beckley Foundation is launching a psilocybin-focused holistic wellbeing company called Beckley Retreats.

Starting this September, Beckley Retreats will offer a self-development program that includes:

  • 4 weeks of virtual preparation
  • A 5-day retreat in Jamaica with 2 psilocybin ceremonies and tons of holistic healing practices
  • 6 weeks of virtual integration to encourage new habits and thought patterns

Led by certified psychotherapists and doctors, the retreat combines Indigenous wisdom with modern science to create an unparalleled experience.

Learn more and reserve your spot here.

Equity initiatives for PTSD treatment

MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS announced that its Phase 3 MDMA trial for PTSD is now fully enrolled at 13 sites across the United States and Israel.

The organization took equity initiatives to ensure that BIPOC and LGBTQ+ individuals are represented in the study, as these individuals are more likely to have PTSD (yet less likely to be diagnosed or have reasonable access to treatment).

PDF of article

Understanding neurodiversity

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMPASS Pathways (CMPS) is funding a psilocybin study to better understand the brain science of neurodiversity.

Using brain imaging and behavioural tasks, researchers will investigate how psilocybin affects the serotonin brain networks in autistic adults compared to non-autistic adults. 

The goal is to understand the unique brain mechanisms associated with autism to provide “better tailored choices” to autistic people.

CMPS shares spiked 11% yesterday after the company announced Q1 financial results, including $21.2M net loss and $243.7M in cash.

PDF of article

How ketamine affects the brain over time

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

The results from Cybin and Kernel’s brain imaging study are in!

The findings suggest that a single dose of ketamine has a lasting effect on the way information flows through the brain.

Subjects’ brain activity patterns were relatively stable for 5 days leading up to the ketamine session.

After a low dose of ketamine, there were significant changes in functional connectivity lasting at least 5 days. 

Top images: Johnson’s absolute functional connectivity for minutes 5-15 after he received the 57.75mg intramuscular injection of Ketamine. Bottom images: Johnson’s relative functional connectivity changes after the Ketamine took effect starting at minutes 15-25. (Graphic: Business Wire)

PDF of article